anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Semaglutide
Trial phase: Phase 4
ATC code: A10BJ06
SMILES: CC[C@H](C)[C@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)C(C)(C)NC(=O)[C@@H](N)Cc1cnc[nH]1)[C@@H](C)O)[C@@H](C)O)C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 3
Group description: Once weekly injection of 1.0mg Semaglutide 4-6 months at prescribed dose

Semaglutide (1 Mg Dose): Weekly injection of study drug for 4-6 months prior to Roux-en-Y gastric bypass surgery
Eligibility criteria:
Inclusion Criteria:

Candidates for Roux-en-Y Gastric Bypass Surgery with an established diagnosis of Type 2 diabetes requiring insulin treatment for glycemic control
Ability to provide informed consent before any trial-related activities

Exclusion Criteria:

Prior metabolic surgery procedure
Use of GLP-1 analogues for diabetes treatment at the time of recruitment
Known or suspected allergy to semaglutide or the excipients in semaglutide, or related products.
Contraindications to semaglutide which include a personal or family history of medullary carcinoma of the thyroid or multiple endocrine neoplasia syndrome-2 (MEN-2)
Previously randomized for participation in this trial.
Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures.
Type 1 diabetes
Intervention: Cholecalciferol
Trial phase: Phase 4
ATC code: A11CC05 | A11CC55 | M05BB03 | M05BB04 | M05BB05 | M05BB07 | M05BB08 | M05BB09 | M05BX53
SMILES: [H][C@@]12CC[C@]([H])([C@H](C)CCCC(C)C)[C@@]1(C)CCC/C2=C\C=C1\C[C@@H](O)CCC1=C
Sex: All
Age groups: Child | Adult
Healthy volunteers: No
Participants at risk: 8
Group description: Cholecalciferol: Mothers in placebo control group will receive 600 IU of vitamin D in the form of their prenatal vitamin along with placebo vitamin D.
Eligibility criteria:
Inclusion Criteria:

Women with documentation of fully breastfeeding who present within one month of delivery, who are 18-45 years old and in good general health will be eligible for participation.
Infants <35 weeks corrected gestational age at birth

Exclusion Criteria:

NO DMI/DMII, HTN, or parathyroid disease IF thyroid issues, currently euthyroid
Multiple gestations
No liver disease
No major congenital abnormalities
No kidney disease
No inborn errors of metabolism
No parathyroid disease
No disorders of calcium metabolism
No antiepileptics
No steroids
No congenital heart disease
No severe illness at birth deemed incompatible with survival
Intervention: Cangrelor
Trial phase: Phase 4
ATC code: B01AC25
SMILES: CSCCNc1nc(SCCC(F)(F)F)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(O)OP(=O)(O)C(Cl)(Cl)P(=O)(O)O)[C@@H](O)[C@H]1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: Ticagrelor loading dose followed after 1 hour by cangrelor bolus and infusion

Cangrelor: Cangrelor will be used at the FDA recommended dose using a 30 μg/kg bolus followed by 4 μg/kg/min infusion. The duration of cangrelor/placebo infusion will be 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase

Placebo: Normal saline will be infused for 2 hours. After completing the first phase of the study, patients will undergo a 1-4 week wash-out period and then will cross-over to the alternative treatment in the second phase
Eligibility criteria:
Inclusion criteria:

Patients with known coronary artery disease (defined as prior type I myocardial infarction, coronary revascularization, percutaneous or surgical, or presence of at least a 50% stenosis in any major epicardial vessel).
Age > 18 years old
On aspirin 81mg/qd for at least 1 month

Exclusion criteria:

Inability to provide written informed consent
Hemodynamic instability
On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 30 days
Known allergies to ticagrelor or cangrelor
Considered at high risk for bleeding
History of intracranial bleeding/hemorrhagic stroke
On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxoban) within past 30 days
Known platelet count <80x106/mL
Known hemoglobin <10 g/dL
Active bleeding
Known end stage renal disease on hemodialysis
Known severe hepatic dysfunction
Acute or severe bronchial asthma or upper airway obstruction.
Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.
Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.
Pregnant females [women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study]
Intervention: Simvastatin
Trial phase: Phase 4
ATC code: A10BH51 | C10AA01 | C10BA02 | C10BA04 | C10BX01 | C10BX04
SMILES: CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Obese subjects with elevated cholesterol

Simvastatin 40mg: Simvastatin administered daily for 6 weeks
Eligibility criteria:
Inclusion Criteria:

Age: 18 to 75 years of age.
Obese (BMI ≥30 kg/m2)
LDL cholesterol of ≥100 mg/dl
Not taking any vitamins or antioxidants

Exclusion Criteria:

Currently using anti-hyperlipidemic therapies
Triglycerides >500 mg/dl.
Myocardial infarction, angioplasty/stent placement or coronary artery bypass surgery in the past 6 months.
Patient on chronic use of non-steroidal anti-inflammatory drugs or steroids
Hepatic disease
Renal impairment.
History of drug or alcohol abuse
Participation in any other concurrent clinical trial
Use of an investigational agent or therapeutic regimen within 30 days of study.
Smoker
Pregnancy
Premenopausal women who are not on birth control pills and have not had a hysterectomy or tubal ligation
Anemia with hemoglobin <12 g/dl
Intervention: Ezetimibe
Trial phase: Phase 4
ATC code: C10AX09 | C10BA02 | C10BA05 | C10BA06 | C10BA10 | C10BA11 | C10BA12
SMILES: [H][C@]1(CC[C@H](O)c2ccc(F)cc2)C(=O)N(c2ccc(F)cc2)[C@]1([H])c1ccc(O)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 10
Group description: Obese subjects with elevated cholesterol

Ezetimibe 10mg: Ezetimibe administered daily for 6 weeks
Eligibility criteria:
Inclusion Criteria:

Age: 18 to 75 years of age.
Obese (BMI ≥30 kg/m2)
LDL cholesterol of ≥100 mg/dl
Not taking any vitamins or antioxidants

Exclusion Criteria:

Currently using anti-hyperlipidemic therapies
Triglycerides >500 mg/dl.
Myocardial infarction, angioplasty/stent placement or coronary artery bypass surgery in the past 6 months.
Patient on chronic use of non-steroidal anti-inflammatory drugs or steroids
Hepatic disease
Renal impairment.
History of drug or alcohol abuse
Participation in any other concurrent clinical trial
Use of an investigational agent or therapeutic regimen within 30 days of study.
Smoker
Pregnancy
Premenopausal women who are not on birth control pills and have not had a hysterectomy or tubal ligation
Anemia with hemoglobin <12 g/dl
Intervention: SULFUR HEXAFLUORIDE
Trial phase: Phase 3
ATC code: V08DA05
SMILES: FS(F)(F)(F)(F)F
Sex: All
Age groups: Child
Healthy volunteers: No
Participants at risk: 4
Group description: Sulfur hexafluoride lipid-type A microspheres: Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
Eligibility criteria:
Inclusion Criteria:

Patient (male/female) hospitalized at the Children's Hospital of Philadelphia (CHOP).
Patient 17 years of age or younger.
Diagnosis of COVID-19 or high clinical suspicion for COVID-19 despite negative tests (according to the definition of probable case by the European Centre for Disease Prevention and Control).
Patients have evidence of cardiovascular compromise, myocardial injury, acute kidney injury and/or new-onset neurological symptoms.
Parental/guardian permission (informed consent)

Exclusion Criteria:

1. Medical history of Lumason hypersensitivity
Intervention: Cannabidiol
Trial phase: Phase 1 | Phase 2
ATC code: N03AX24
SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 21
Group description: After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.

Epidiolex 100 mg/mL Oral Solution: Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
Eligibility criteria:
Inclusion Criteria:

Healthy adults 18-75 years old, ASA I or II
permanent tooth with moderate to severe odontogenic pain, i.e. ≥30 on a 100mm VAS,
clinical pulpal diagnosis of irreversible pulpitis or pulpal necrosis, and periapical diagnosis of symptomatic apical periodontitis
test negative for recent cannabis use and/or other drugs of abuse including alcohol (urine tests collected at screening visit), and participant
able to understand the forms (English or Spanish) and provide informed written consent.

Exclusion Criteria:

ASA Class III or IV
patients with hepatic impairment
pregnant or lactating women
Patients on drugs metabolized by enzymes that also metabolize CBD (e.g. clobazam, diazepam, topiramate, warfarin)
self-reported prior experience inhaling cannabis (either via smoking or vaporization), use of opioids in the month prior to screening/treatment visit, and/or NSAIDS or acetaminophen 6 hours prior to treatment
unwilling to participate.
Intervention: Cannabidiol
Trial phase: Phase 1 | Phase 2
ATC code: N03AX24
SMILES: C=C(C)[C@@H]1CCC(C)=C[C@H]1c1c(O)cc(CCCCC)cc1O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 20
Group description: The 20mg/kg dose is the maximum recommended daily dose from the manufacturer. After drug administration, subjects will be monitored for 3 hours, and pain intensity and safety data will be collected at various time points. Ibuprofen 600mg (or acetaminophen/codeine 650/60mg, if a contraindication for ibuprofen exists) will be provided in the 3-hour observation period as rescue medication if needed. Subjects will be encouraged to wait at least 60min after administration of the drug study before consuming the rescue medication. It will be given at the patient's request. If rescue medication was required, the study drug will still be dosed as per protocol, and time-to -rescue analysis will be performed. Then, the recommended root canal therapy will be performed the same or the next day.

Epidiolex 100 mg/mL Oral Solution: Cannabidiol (CBD): is the primary non-psychoactive and non-addictive compound in cannabis, has already shown potential in treating pain such as arthritis, neuropathic, cancer and chronic pain
Eligibility criteria:
Inclusion Criteria:

Healthy adults 18-75 years old, ASA I or II
permanent tooth with moderate to severe odontogenic pain, i.e. ≥30 on a 100mm VAS,
clinical pulpal diagnosis of irreversible pulpitis or pulpal necrosis, and periapical diagnosis of symptomatic apical periodontitis
test negative for recent cannabis use and/or other drugs of abuse including alcohol (urine tests collected at screening visit), and participant
able to understand the forms (English or Spanish) and provide informed written consent.

Exclusion Criteria:

ASA Class III or IV
patients with hepatic impairment
pregnant or lactating women
Patients on drugs metabolized by enzymes that also metabolize CBD (e.g. clobazam, diazepam, topiramate, warfarin)
self-reported prior experience inhaling cannabis (either via smoking or vaporization), use of opioids in the month prior to screening/treatment visit, and/or NSAIDS or acetaminophen 6 hours prior to treatment
unwilling to participate.
Intervention: Bupivacaine
Trial phase: Phase 4
ATC code: N01BB01 | N01BB10 | N01BB51 | N01BB59
SMILES: CCCCN1CCCCC1C(=O)Nc1c(C)cccc1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Patients in this group will be given the study drug (liposomal bupivacaine).

Liposomal bupivacaine: Patients included in the treatment group will have their incisional site infused, targeting the paraspinal muscles with liposomal bupivacaine at the end of their surgery.
Eligibility criteria:
Inclusion Criteria:

Patients undergoing isolated lumbar spine procedures using a posterior approach.
Surgical spine procedures include:
Single-level lumbar spine surgeries with or without fusion
Multi-level lumbar spine surgeries with or without fusion

Exclusion Criteria:

Procedures involving intrathecal space
Patients with documented allergy to local anesthetics (bupivacaine, lidocaine, procaine, benzocaine).
Acute lumbar trauma that requires immediate spine stabilization
Revision of failed back surgeries (including nonunion and malunion)
Revision of wound or hardware
Contraindication to regional anesthesia
Patients with chronic use of opioid medications
Liver dysfunction (INR > 1.5, albumin <2.8g/dl, bilirubin >2mg/dl)
Renal dysfunction (eGFR < 60ml/min/1.73m2)
Severe chronic obstructive pulmonary disease requiring continuous oxygen supplementation
Unable to give informed consent
Pregnancy
Intervention: SODIUM CHLORIDE
Trial phase: Phase 4
ATC code: A12CA01 | B05CB01 | B05XA03 | S01XA03
SMILES: [Cl-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 34
Group description: Patients in this group will be given the placebo (sterile saline).

saline 0.9%: Patients included in the placebo group will have their incisional site infused, targeting the paraspinal muscles with sterile saline at the end of their surgery.
Eligibility criteria:
Inclusion Criteria:

Patients undergoing isolated lumbar spine procedures using a posterior approach.
Surgical spine procedures include:
Single-level lumbar spine surgeries with or without fusion
Multi-level lumbar spine surgeries with or without fusion

Exclusion Criteria:

Procedures involving intrathecal space
Patients with documented allergy to local anesthetics (bupivacaine, lidocaine, procaine, benzocaine).
Acute lumbar trauma that requires immediate spine stabilization
Revision of failed back surgeries (including nonunion and malunion)
Revision of wound or hardware
Contraindication to regional anesthesia
Patients with chronic use of opioid medications
Liver dysfunction (INR > 1.5, albumin <2.8g/dl, bilirubin >2mg/dl)
Renal dysfunction (eGFR < 60ml/min/1.73m2)
Severe chronic obstructive pulmonary disease requiring continuous oxygen supplementation
Unable to give informed consent
Pregnancy
Intervention: Gentamicin
Trial phase: Phase 4
ATC code: D06AX07 | J01GB03 | S01AA11 | S02AA14 | S03AA06
SMILES: CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 19
Group description: Participants scheduled for Revision Total Shoulder Arthroplasty (TSA) will receive two injections of TXA.

Tranexamic acid (TXA) injection: IV, Total Dosage: 2 grams (1 gram before surgical incision + 1 gram, 3 hours after first dose)
Eligibility criteria:
Inclusion Criteria:

Patients older than 18 years old
Patients younger than 90 years old
Patients undergoing scheduled revision total shoulder arthroplasty
Patients who consent to be randomized

Exclusion Criteria:

Patients younger than 18
Patients older than 90 years old
Patients who are pregnant or breast-feeding women
Patients who are allergic to tranexamic acid
Patients with proximal humerus fracture or fracture sequelae
Patients who use estrogen containing medications (i.e. oral contraceptive pills)
Patients who have acquired disturbances of color vision

Patients with a history of any of the following diagnosis: '

Subarachnoid hemorrhage
Active intravascular clotting
Severe pulmonary disease (FEV <50% normal)
Plasma creatinine > 115 μmol/L in males, > 100 μmol/L in females, or hepatic failure)
(Renal impairment serum creatinine > 1.5 times the upper limit of normal NYU)
Preoperative anemia [Hemoglobin (Hb) < 11g/dL in females, Hb < 12 g/dL in males]
Patients who refuse blood products
Patients undergoing hormone replacement therapy
Patients with diagnosed or self-reported cognitive dysfunction;
Patients who are unable to understand or follow instructions;
Patients with severe liver disease, renal insufficiency, congestive heart failure, and/or significant heart disease;
Patients with BMI over 50
Any patient that the investigators feel cannot comply with all study related procedures.
Intervention: Camostat
Trial phase: Phase 1
ATC code: B02AB04
SMILES: CN(C)C(=O)COC(=O)Cc1ccc(OC(=O)c2ccc(NC(=N)N)cc2)cc1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 2
Group description: SARS-CoV-2 positive participants will receive SOC therapy as well as camostat for 7 days.

Camostat Mesilate: Camostat 600mg by mouth four times a day, for a total of 7 days
Eligibility criteria:
Inclusion Criteria:

>= 60 years of age
COVID-19 infection, confirmed by polymerase chain reaction (PCR) test <=5 days from enrollment done in the ambulatory setting
Able to provide informed consent
Symptom related to COVID-19. This includes: fever or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea or vomiting, diarrhea or other symptom recognized by the Centers for Disease Control to be a symptom of COVID-19.

Exclusion Criteria:

Patients who undergo asymptomatic screening test that is positive and remain asymptomatic during the eligible time window
Patients who have had one or more positive more than 5 days prior to enrollment but within 60 days of enrollment (ex. if a patient has a positive test 10 days prior to enrollment and then a second positive test the day referred for enrollment, that patient would be excluded. If a patient had a positive test 5 months ago, and then another positive test the day he/she was referred for enrollment, that patient would be eligible)
Unable to take oral medication
Male patients with female partners of reproductive potential who are unable to maintain effective contraception during the recommended time period (during treatment and for 130 days after the final dose)
Symptoms requiring hospitalization or immediate referral to hospital
Taking bicalutamide, any systemic hormonal therapy, or camostat within one month of study entry
Known hypersensitivity to bicalutamide, or camostat, or its components.
On coumadin anticoagulation (because of drug-drug interaction with bicalutamide)
Self-reported past medical history of chronic liver disease or cirrhosis
Self-reported myocardial infarction within 6 months or past medical history of congestive heart failure with known ejection fraction < 40%
Taking any other investigational treatment for COVID-19 or COVID-19 prophylaxis (COVID-19 vaccines and treatments allowed under FDA Emergency Use Authorization are allowed.)

Women and people from all ethnic and race groups are eligible for this study.
Intervention: CID 163285897
Trial phase: Phase 3
ATC code: A10BX16
SMILES: CCC(C)C(NC(=O)C(CC(C)C)NC(=O)C(Cc1c[nH]c2ccccc12)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(C)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(N)Cc1ccc(O)cc1)C(C)O)C(C)O)C(C)CC)C(C)CC)C(C)C)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N1CCCC1C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(CO)C(N)=O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 311
Group description: Participants received 15 mg Tirzepatide administered SC QW.
Eligibility criteria:
Inclusion Criteria:

Have Type 2 Diabetes (T2DM) with HbA1c ≥7% to ≤10% at screening, on stable therapy for the last 3 months prior to screening. T2DM may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling) EXCEPT dipeptidyl peptidase 4 (DPP-4) inhibitors or glucagon like peptide-1 receptor agonists (GLP-1 RAs)
Have a BMI of ≥27 kg/m²
Are overweight or have obesity
Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight
Are at least 18 years of age and age of majority per local laws and regulations

Exclusion Criteria:

Have Type 1 diabetes mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except T2DM
Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values >270 mg/dL(on 2 nonconsecutive days) prior to Visit 3
Have proliferative diabetic retinopathy OR diabetic macular edema OR non-proliferative diabetic retinopathy that requires acute treatment
Have self-reported change in body weight >5kg within 3 months prior to screening
Have had a history of chronic or acute pancreatitis
Change in body weight greater than 5 kg within 3 months prior to starting study
Obesity induced by other endocrinologic disorders or monogenetic or syndromic forms of obesity
Family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder within the last 2 years
Any lifetime history of a suicide attempt